Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK [mitogen-activated protein kinase] Inhibitor GSK1120212 in Subjects With Solid Tumors or Lymphoma.

Next Previous
Search
Trial Profile

An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK [mitogen-activated protein kinase] Inhibitor GSK1120212 in Subjects With Solid Tumors or Lymphoma.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trametinib (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 21 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Sep 2011 New source identified and integrated (M.D. Anderson Cancer Center record, 2009-0660).
    • 10 Dec 2010 Planned end date changed from 1 Sep 2009 to 1 May 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top